Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department

Tommaso Bucci1 · Gioacchino Galardo1 · Orietta Gandini2 · Tommasa Vicario1,3 · Carla Paganelli3 · Sara Cerretti4 · Chiara Bucci4 · Francesco Pugliese4 · Daniele Pastori4 · the Research On Medical patients Admitted to the Emergency Department (ROMA-ED) study group

Received: 12 March 2022 / Accepted: 20 April 2022 / Published online: 27 May 2022 © The Author(s) 2022

Abstract
Liver damage worsens the prognosis of coronavirus 19 disease (COVID-19). However, the best strategy to stratify mortality risk according to liver damage has not been established. The aim of this study is to test the predictive value of the validated Fibrosis-4 (FIB-4) Index and compared it to liver transaminases and to the AST-to-Platelet ratio index (APRI). Multicenter cohort study including 992 consecutive COVID-19 patients admitted to the Emergency Department. FIB-4 > 3.25 and APRI > 0.7 were used to define liver damage. Multivariable Cox regression and ROC curve analysis for mortality were performed. Secondary endpoints were (1) need for high-flow oxygen and (2) mechanical ventilation. 240 (24.2%) patients had a FIB-4 > 3.25. FIB-4 > 3.25 associated with an increased mortality (n = 119, log-rank test p < 0.001 and adjusted hazard ratio (HR) 1.72 (95% confidence interval [95%CI] 1.14–2.59, p = 0.010). ROC analysis for mortality showed that FIB-4 (AUC 0.734, 95% CI 0.705–0.761) had a higher predictive value than AST (p = 0.0018) and ALT (p < 0.0001). FIB-4 > 3.25 was also superior to APRI > 0.7 (AUC 0.58, 95% CI 0.553–0.615, p = 0.0008). Using an optimized cut-off > 2.76 (AUC 0.689, 95% CI 0.659–0.718, p < 0.0001), FIB-4 was superior to FIB-4 > 3.25 (p = 0.0302), APRI > 0.7 (p < 0.0001), AST > 51 (p = 0.0119) and ALT > 42 (p < 0.0001). FIB-4 was also associated with high-flow oxygen use (n = 255, HR 1.69, 95% CI 1.25–2.28, p = 0.001) and mechanical ventilation (n = 39, HR 2.07, 95% CI 1.03–4.19, p = 0.043). FIB-4 score predicts mortality better than liver transaminases and APRI score. FIB-4 score may be an easy tool to identify COVID-19 patients at worse prognosis in the emergency department.

Keywords COVID-19 · FIB-4 · Liver fibrosis · AST · ALT

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may cause a systemic inflammatory disease causing not only acute respiratory failure but also multi-organ damage. This is the consequence of the ubiquitous distribution of the angiotensin converting enzyme 2 (ACE2) [1], and to the systemic release of pro-inflammatory [2] and pro-thrombotic compounds [3]. Indeed, there have been described several cases of cardiac, renal and liver involvement during the coronavirus 19 disease (COVID-19) [4].

In particular, the presence of liver damage seems to be quite common in COVID-19 patients with an estimated prevalence of patients with elevated aspartate aminotransferase (AST) of 23.2% and alanine aminotransferase (ALT) of 21.2% [5]. In addition, several evidence suggested that liver injury is associated with a more severe SARS-CoV-2
infection [6–8], especially when liver damage was defined by raised AST [5]. The presence of liver damage was also shown to represent a negative prognostic factor for COVID-19 patients [9, 10]. However, previous studies on COVID-19 patients mostly used liver transaminases to define liver damage and to describe its association with mortality risk [9].

However, it has become evident that non-invasive scores may identify patients with liver impairment better than liver transaminases. In this context, the Fibrosis-4 (FIB-4) Index and AST-to-Platelet ratio index (APRI) are the two most widely investigated scores that showed a good correlation with the presence of liver fibrosis detected at liver biopsy in different clinical settings, including viral hepatitis, alcoholic and non-alcoholic fatty liver disease [11]. The advantage of these non-invasive scores is to detect relevant liver damage also in patients with nearly normal or only mild elevation of liver transaminases and may save a significant number of unnecessary liver biopsy procedures.

In addition, previous studies showed that these non-invasive scores may have a prognostic role for cardiovascular events and mortality both in liver [12] and non-liver diseases [13].

Scarce data on the COVID-19 population have been reported so far; one previous study showed that FIB-4 was associated with the need for mechanical ventilation but no data on mortality were reported [14]. Conversely, studies on mortality risk according to FIB-4 included a relatively small sample or specific subgroups of patients, such as those with liver steatosis [15, 16] or haematological malignancies [17], and used different cut-off of FIB-4, making results of difficult comparison [18]. Given the still wide-spread diffusion of SARS-CoV-2 infection, more data allowing a better risk stratification strategy and eventually sources allocation, are warranted.

To this aim, we compared the prognostic value of liver transaminases, FIB-4 and APRI score with mortality risk in a large population of consecutive COVID-19 patients admitted to the Emergency Department of two University Hospitals in Rome.

The following data were collected from at the time of COVID-19 diagnosis in the emergency department: demographic, comorbidities, clinical, laboratory and radiological findings. Patients underwent a routine laboratory screening at the entry of the Emergency Department including, complete blood count (CBC), lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, D-dimer, creatinine with estimated Glomerular Filtration Rate (eGFR) estimation (MDRD formula), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), GGT. Chronic kidney disease (CKD) was defined by and eGFR < 60 ml/min. An arterial blood gas analysis was also obtained and the corresponding PaO2/FiO2 ratio evaluated.

Radiological findings

All patients underwent high-resolution chest computed tomography (CT) to evaluate the presence of interstitial pneumonia and its severity. Patients were classified as (1) no pneumonia if there was no radiological sign of pneumonia, (2) mild pneumonia if there was only interstitial involvement without consolidation, (3) moderate pneumonia if there was interstitial involvement with consolidation in less of 50% of lung parenchyma and (4) severe pneumonia if there was interstitial involvement and consolidation in more than 50% of lung parenchyma.

Non-invasive scores

FIB-4 score was calculated as follows: age year × AST (U/L)/Platelet Count (1000/L) × √ALT (U/L). A cut-off of > 3.25 was used to define liver damage. For the analysis, a specific cut-off of > 2.76 for the study cohort was obtained from ROC analysis. As a second marker we calculated the APRI score as follows: [(AST/upper limit of the normal AST range) × 100]/Platelet Count. A cut-off of > 0.70 was used to define liver damage.

Follow-up and mortality

After the initial evaluation and management, patients were discharged in home isolation or were hospitalized in low, medium or sub-intensive/intensive care units according to medical needs. All patients were followed up to 60 days after the Emergency Department admission. The principal endpoint of the study was all-cause mortality. Deaths were double checked on electronic records.

In keeping with statements by the Italian Regulatory Authorities (https://www.garan tepri vacy.it/web/guest/home/docweb b/~/docweb-display/docweb b/5805552), anonymised data were retrospectively collected from medical and electronic databases in the context of an audit. Patients were not directly involved in any phase of the study.

Patients and methods

We carried out a retrospective multicenter cohort study including on 992 patients, affected by COVID-19, admitted to the Emergency Department of Umberto I University Hospital in Rome and from Tor Vergata University Hospital of Rome from March to October 2020. All patients were diagnosed with COVID-19 after two positive polymerase chain reaction tests on nasopharyngeal swab specimens. Patients aged < 18 years were excluded, as well as patients with history of liver cirrhosis. To limit bias, no additional exclusion criteria were applied.
A waiver of informed consent from study participants is applied for retrospective studies. The study was conducted in accordance with the principles embodied in the Declaration of Helsinki.

**Statistical analysis**

Continuous variables are reported as mean and standard deviation or median and interquartile range depending on variable distribution. Means and medians were compared by Student’s *t* test or the Mann–Whitney *U* test, respectively. Categorical variables were reported as count and percentage and compared by Pearson chi-squared test. A first descriptive analysis of clinical, biochemical and radiological characteristics of patients was performed according to the presence of FIB-4 above or below 3.25.

We then analysed factors associated with mortality risk using univariable and multivariable Cox proportional hazard regression analysis with forward stepwise selection procedure. For the analysis, linear variables were categorised into tertiles. Only variables with complete data available were used for the multivariable model.

We also built the receiver operating characteristic (ROC) curves to test the predictive value of FIB-4, APRI, AST and ALT against in-hospital mortality. Area under the curve (AUC) values were calculated using the method described by Delong et al. [19]. In addition, we used the ROC curve with Youden index to find the optimal cut off for FIB-4 (> 2.76), AST (> 51) and ALT (> 42) against mortality. Secondary endpoints were the need for high flow oxygen, such as non-invasive ventilation (NIV) or high flow nasal cannula (HFNC) and mechanical ventilation. Multivariable models for secondary endpoints were adjusted for the same variables as for the primary one. The statistical significance was set at a *p* value < 0.005. All the analyses were performed using the IBM software SPSS 25.0 and MedCalc®.

**Results**

**Clinical characteristics**

The demographics and clinical characteristics of COVID-19 patients according to the FIB-4 score are shown in Table 1. In the whole cohort, 240 had a FIB-4 > 3.25 (24.2%). Patients with FIB-4 > 3.25 were older and showed a higher prevalence of hypertension, diabetes, heart failure and active cancer. Regarding the clinical presentation, they presented more frequently fever, low peripheral oxygen saturation, signs of severe respiratory failure (PaO2/FiO2 ratio < 200) and extensive pneumonia at the high-resolution chest CT (Table 1). Amongst the laboratory variables, patients with FIB-4 > 3.25 had a lower median eGFR, lymphocytes and platelet count and a higher median concentration of D-dimer, serum ferritin, CRP and LDH. At baseline, patients with high FIB-4 were taking a higher number of cardiovascular drugs (Table 1). Regarding the COVID-19 treatment modalities, no differences were noted about anticoagulation and steroids prescription.

**Primary outcome**

After the initial evaluation, patients with FIB-4 < 3.25 were more frequently discharged at home or hospitalized in low-intensity care units while patients with FIB-4 > 3.25 were more often hospitalized in sub-intensive and intensive care units (Supplementary table 1). In our population of COVID-19, the mean follow-up was 50 ± 18 days. During follow-up 119 deaths (13%) were recorded. The prevalence of FIB-4 > 3.25 was higher in non-survivor vs survivor patients (51.3% vs. 20.5%; *p* < 0.0001). Patients with FIB-4 > 3.25 showed a higher incidence of death than patients with FIB-4 < 3.25 (7.6% vs. 25.4%; log-rank test *p* < 0.001; Fig. 1). At univariable regression analysis (Supplementary Table 1), factors associated with mortality were age > 70 years. hypertension, diabetes, heart failure, COPD, cancer, CKD, PaO2/FiO2 < 200, CT signs of severe pneumonia, lymphocytes < 0.6 × 10⁹/µL, high D-dimer > 937 ng/mL, serum ferritin > 914 ng/mL, CRP > 6.3 mg/dL, LDH, eGFR, AST, ALT and FIB-4 > 3.25 (Supplementary Table 1). In the multivariable regression model, CKD, PaO2/FiO2 < 200, CRP > 6.3 mg/dL and FIB-4 > 3.25 were independently associated with mortality (Table 2).

**ROC analysis**

At ROC analysis (Table 3), FIB-4 score, as a continuous variable, showed a higher predictive value than AST and ALT (AUC 0.73, 0.64 and 0.51, respectively, Supplementary Fig. 1). FIB-4 > 3.25 was superior to ALT and APRI > 0.7 in predicting mortality (Fig. 2). In particular, we found that the optimal cut-off of > 2.76, obtained from the ROC analysis, was superior to FIB-4 > 3.25, APRI > 0.7 and both ALT and AST even when optimal cut-offs for these variables were used (Fig. 2).

**Secondary outcomes**

Patients with FIB-4 > 3.25 require more often oxygenation with HFNC, NIV or mechanical ventilation (Supplementary Table 2).
Table 1 Comparison of patients with SARS-CoV-2 infection based on FIB-4 score

| Variables                        | Total population n = 992% (n) | FIB-4 < 3.25 n = 752% (n) | FIB-4 > 3.25 n = 240% (n) | p       |
|----------------------------------|-------------------------------|---------------------------|---------------------------|---------|
| Age (years)                      | 61 (54–70)                    | 57 (51–64)                | 76 (70–81)                | <0.001  |
| Women                            | 39.6 (393)                    | 41.2 (310)                | 34.6 (83)                 | 0.067   |
| Arterial hypertension            | 34.3 (341)                    | 30.6 (230)                | 46.2 (111)                | <0.001  |
| Diabetes                         | 19.1 (189)                    | 16.2 (122)                | 28.6 (67)                 | <0.001  |
| Heart failure (N = 641)          | 9.4 (60)                      | 7.6 (36)                  | 14.5 (24)                 | 0.013   |
| COPD (N = 919)                   | 9.1 (84)                      | 8.3 (58)                  | 11.8 (26)                 | 0.114   |
| Cancer                           | 5.7 (57)                      | 4.5 (34)                  | 9.6 (23)                  | 0.003   |
| Concomitant treatments<sup>a</sup>|                               |                           |                           |         |
| Proton pump inhibitor            | 16.9 (90)                     | 12.8 (52)                 | 29.5 (38)                 | <0.001  |
| ACE inhibitors                   | 15.0 (80)                     | 13.1 (53)                 | 20.8 (27)                 | 0.047   |
| Sartans                          | 11.6 (62)                     | 10.9 (44)                 | 13.8 (18)                 | 0.348   |
| Diuretics                        | 6.9 (37)                      | 4.7 (19)                  | 13.8 (18)                 | 0.001   |
| Statins                          | 11.8 (63)                     | 8.9 (36)                  | 20.8 (27)                 | 0.001   |
| Calcium channel blockers         | 8.8 (47)                      | 7.9 (32)                  | 11.5 (15)                 | 0.214   |
| Beta-blockers                    | 13.1 (70)                     | 11.1 (45)                 | 19.2 (25)                 | 0.024   |
| Antplatelet                      | 15.0 (80)                     | 10.6 (43)                 | 28.5 (37)                 | <0.001  |
| Insulin                          | 4.2 (15)                      | 3.1 (9)                   | 9.0 (6)                   | 0.043   |
| Vital signs                      |                               |                           |                           |         |
| Heart rate                       | 88 (80–94)                    | 88 (80–94)                | 88 (80–94)                | 0.727   |
| Systolic blood pressure          | 130 (120–130)                 | 130 (120–130)             | 130 (120–130)             | 0.448   |
| Diastolic blood pressure         | 70 (70–80)                    | 70 (70–80)                | 70 (70–80)                | 0.224   |
| O₂ saturation                    | 97 (96–98)                    | 97 (96–98)                | 95.5 (93–97)              | <0.001  |
| Temperature (°C)                 | 37 (36.5–37.5)                | 37 (36.5–37.5)            | 37.3 (36.8–38)            | 0.001   |
| pO₂                              | 74 (66–98)                    | 77 (69–86)                | 66 (56–75)                | <0.001  |
| PaO₂/FiO₂                         | 295 (251–388)                 | 357 (266–400)             | 258 (210–291)             | <0.001  |
| PaO₂/FiO₂ < 200                   | 18 (179)                      | 13.6 (102)                | 32.1 (77)                 | <0.001  |
| Radiological findings            |                               |                           |                           |         |
| No pneumonia                      | 9 (89)                        | 10.8 (81)                 | 3.3 (8)                   | <0.001  |
| Mild pneumonia                    | 23.3 (231)                    | 25.3 (190)                | 17.1 (25.3)               |         |
| Moderate pneumonia                | 42.4 (421)                    | 40.8 (307)                | 47.5 (114)                |         |
| Severe pneumonia                  | 25.4 (252)                    | 23.1 (174)                | 32.1 (77)                 |         |
| Laboratory findings              |                               |                           |                           |         |
| White blood cell (× 10⁹/µL)       | 5.9 (5–7.1)                   | 6.03 (5.1–7.3)            | 5.3 (4.2–6.8)             | <0.001  |
| Neutrophils (× 10⁹/µL)           | 3.9 (3–5.1)                   | 4.1 (3.1–5.2)             | 3.7 (2.5–4.8)             | 0.004   |
| Lymphocytes (× 10⁹/µL)           | 0.9 (0.6–1.1)                 | 0.9 (0.7–1.2)             | 0.7 (0.5–0.9)             | <0.001  |
| Platelets (× 10⁹/µL)             | 187 (162–220)                 | 207 (178–236)             | 142.5 (120.3–158.6)       | <0.001  |
| Platelets < 150 (× 10⁹/µL)       | 24.2 (240)                    | 13.3 (100)                | 58.3 (140)                | <0.001  |
| D-dimer (ng/mL) (N = 762)        | 664 (464–937)                 | 606 (431–816)             | 973 (606–1456)            | <0.001  |
| Ferritin (ng/mL) (N = 453)       | 595 (383–914)                 | 535 (354–841)             | 829 (536–1339)            | <0.001  |
| C-reactive protein (mg/dL) (n = 766) | 3.7 (1.8–6.3)          | 3.2 (1.3–5.6)             | 6 (3.7–9.2)               | <0.001  |
| LDH (U/L) (n = 865)              | 289 (228.5–387.5)             | 282.5 (223–371)           | 401 (260.5–560.5)         | <0.001  |
| Alanine aminotransferase (U/L)   | 24 (18–32)                    | 25 (18–34)                | 22 (16–30)                | 0.020   |
| Aspartate aminotransferase (U/L) | 31 (25–38)                    | 28 (23–35)                | 40 (33–49)                | <0.001  |
| GGT (U/L) (N = 584)              | 28 (20–41)                    | 28 (21–39.3)              | 26 (18–44)                | 0.683   |
| eGFR (mL/min)                    | 81 (70–92.4)                  | 87.1 (74.9–96)            | 65 (51.3–77.5)            | <0.001  |

<sup>a</sup>Data available in 535 patients (405 with FIB-4 <3.25 and 130 with FIB-4 > 3.25)
Overall, 255 (25.7%) patients were treated with HFNC/NIV, 20.5% of survivors vs. 69.7% of non-survivors ($p < 0.001$). Univariable HR for FIB-4 $> 3.25$ for HFNC/NIV was 2.72, 95% CI 2.12–3.49, $p < 0.001$. FIB-4 $> 3.25$ remained associated with an increased risk for HFNC/NIV in the multivariable model (HR 1.69, 95% CI 1.25–2.28, $p = 0.001$. Supplementary Table 2).

Thirty-nine (3.9%) patients underwent mechanical ventilation, 1.9% of survivors and 18.5% of non-survivors. Univariable HR for FIB-4 $> 3.25$ for mechanical ventilation was 3.24, 95% CI 1.72–6.08, $p < 0.001$. FIB-4 $> 3.25$ remained associated with an increased risk for mechanical ventilation in the multivariable model (HR 2.07, 95% CI 1.03–4.19, $p = 0.043$. Table 3).

**Discussion**

In this multicenter cohort study, we found that the FIB-4 may be an easy and accurate tool to predict mortality in patients with COVID-19. We showed that the FIB-4 was superior to liver transaminases alone or to APRI score to predict mortality, especially when a COVID-19 adapted cut-off of FIB-4 was tested.

A first meaningful result is that nearly 25% of patients hospitalized with COVID-19 showed a high FIB-4 $> 3.25$ and 31.4% for FIB-4 $> 2.76$, suggesting that a high proportion of patients may have an early liver involvement during COVID-19. This figure is similar to that reported in a smaller cohort of 202 COVID-19 patients in which the prevalence of FIB-4 $> 2.67$ was 31.2% [18]. In addition, in a study using a FIB-4 cut off $> 2.91$ the prevalence of high FIB-4 was 24.9% [15].

Patients with a high FIB-4 were older, with a high prevalence of comorbidities including arterial hypertension and diabetes. Furthermore, FIB-4 patients had a more severe clinical presentation of COVID-19 as shown by a lower pO2 and PaO2/FiO2. They also showed a pro-inflammatory and pro-thrombotic phenotype as shown by increased D-Dimer, CRP, Ferritin, all features associated with severe respiratory failure [20–22].

---

**Table 2 Multivariable Cox proportional hazards regression analysis for mortality (A), HFNC/NIV (B), mechanical ventilation (C)**

| Variable       | Hazard ratio | 95% Confidence interval | $p$  |
|----------------|--------------|-------------------------|------|
| Mortality      |              |                         |      |
| FIB-4 $> 3.25$ | 1.72         | 1.14–2.59               | 0.010|
| Age $> 70$ years | 2.92         | 1.81–4.72               | < 0.001|
| Female sex     | 0.88         | 0.60–1.31               | 0.533|
| Diabetes       | 1.51         | 1.03–2.23               | 0.036|
| Arterial hypertension | 2.02      | 1.35–3.00               | 0.001|
| Cancer         | 1.80         | 1.02–3.18               | 0.043|
| PaO2/FiO2 $< 200$ | 3.68       | 2.53–5.36               | < 0.001|
| Lymphocytes $< 0.6$ (× 10^3/µL) | 0.91      | 0.61–1.34               | 0.628|
| HFNC/NIV       |              |                         |      |
| FIB-4 $> 3.25$ | 1.69         | 1.25–2.28               | 0.001|
| Age $> 70$ years | 1.10         | 0.81–1.49               | 0.555|
| Female sex     | 0.81         | 0.62–1.07               | 0.144|
| Diabetes       | 1.21         | 0.91–1.62               | 0.188|
| Arterial hypertension | 1.66      | 1.27–2.18               | < 0.001|
| Cancer         | 1.69         | 1.05–2.73               | 0.030|
| PaO2/FiO2 $< 200$ | 9.91       | 7.52–13.06              | < 0.001|
| Lymphocytes $< 0.6$ (× 10^3/µL) | 0.85      | 0.65–1.10               | 0.221|
| Mechanical ventilation |              |                         |      |
| FIB-4 $> 3.25$ | 2.07         | 1.03–4.19               | 0.043|
| Age $> 70$ years | 2.65         | 1.29–5.46               | 0.008|

---

**Table 3 ROC curve analysis**

| Variables     | AUC | 95% Confidence interval | $p$ value |
|---------------|-----|-------------------------|----------|
| FIB-4 (continuous) | 0.73 | 0.71–0.76               | <0.0001  |
| FIB-4 $> 3.25$     | 0.66 | 0.62–0.68               | <0.0001  |
| FIB-4 $> 2.76$     | 0.69 | 0.66–0.72               | <0.0001  |
| APRI (continuous)  | 0.64 | 0.61–0.67               | <0.0001  |
| APRI $> 0.7$       | 0.58 | 0.55–0.62               | 0.0003   |
| AST (continuous)   | 0.64 | 0.61–0.67               | <0.0001  |
| AST $> 51$         | 0.62 | 0.59–0.65               | <0.0001  |
| ALT (continuous)   | 0.51 | 0.48–0.54               | 0.8176   |
| ALT $> 42$         | 0.54 | 0.51–0.57               | 0.0897   |
When we analyzed clinical outcomes, we found a mortality rate of 13% within 60 days from the admission to the emergency department. This finding is slightly higher than the 10.9% reported in the study by Li Y. et al. [18] and 10.8% in the study by Younossi et al. [15]. Of note, we found a higher prevalence of increased FIB-4 in patients who died compared to survivors. This association persisted in the multivariable survival model after adjustment for potential confounders and for the severity of respiratory failure. In particular, when we built the ROC curves for mortality, we found an AUC of 0.73 for the FIB-4 score that is in line with recent studies [23, 24].

A novel finding of this work relies on the comparison of the prognostic role of the FIB-4 score for mortality with liver transaminases and with another commonly used score such as the APRI score. We firstly examined the cut-off of 3.25 as it is the most widely used in previous studies, and we found that it was significantly associated with mortality. Furthermore, it allowed a better prediction of mortality than ALT and APRI > 0.7. Then from ROC curve analysis, we found that in this patients' population, a value > 2.76 showed the best combination of sensitivity and specificity. We repeated survival analysis using this optimized cut-off and found an improvement in risk prediction compared to the 3.25 value and to AST, ALT and APRI also using optimized cut-offs for these variables. The predictive value for mortality of the FIB-4 score seems also to be higher than other previously tested scores for mortality in COVID-19 patients, namely WHO severity scale, NEWS, CURB-65 and APACHE scores (all AUC values < 0.66) [25].

We also analyzed the association between a high FIB-4 and indexes of severe COVID-19, such as the need for high oxygen flow and mechanical ventilation. We found that FIB-4 patients had a nearly doubled risk of being treated with high oxygen flow or of needing mechanical ventilation. This association was similar to that reported in a recent study, which reported a 6% of mechanical ventilation and using a cut-off for high FIB-4 set at 3.04 [14].

Our results suggest that liver damage, when evaluated by the FIB-4 score, may be a risk factor for mortality independently from the severity of COVID-19. Indeed, FIB-4, that is calculated using routine laboratory variables, may be an easy prognostic tool to stratify mortality risk in COVID-19 patients admitted to the emergency department.

Limitations and strengths. Our study evaluated the presence of liver damage only at admission, so we do not know whether in some cases liver damage was worsened by concomitant treatments during the hospital stay or if it persisted after the acute phase of COVID-19. We do not have data on viral infections as they are not routinely tested in the emergency department. Our cohort is composed by Caucasian patients only and, therefore, our findings may not apply to other ethnic groups. The retrospective nature of the study does not allow to establish any cause–effect relationship. However, we analysed a quite large cohort of consecutive unselected patients referring to the emergency unit, so that our cohort is representative of patients encountered in daily clinical practice. Furthermore, the cohort is well characterized as all patients underwent CT chest scan, blood gas analysis and an accurate medical personal history collection. Finally, data were collected from medical records and not from ICD codes.

We conclude, the FIB-4 score showed a good predictive value for mortality in patients admitted to the Emergency
Department for COVID-19. Its use may help physicians to early identify patients at higher risk for a more severe disease and at higher risk of mortality.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11739-022-02997-9.

Acknowledgements Research On Medical patients Admitted to the Emergency Department (ROMA-ED) study group.: Elisa Fante, Fabrizio Urso, Enrico Baldini, Laura Zinnamosca, Maria Alessandrini, Grazia Louidice, Chiara Boccardo, Enrico Petritillo, Giada Della Grotta, Leonardo Magrini, Marina Colzi, Cristiana Gianni, Federica Biamonte, Antonio Concistrè, Antonella Ponizio, Cristiana Franchi, Cristiano Marinelli, Tecla Pecci, Flavia Fabi, Giona Roma, Alessandra Massi, Alina Dziazenko, Mauro Casagrande. Emanuela Bresciani, Marianna Suppa, Adriana Servello, Alessandro Coppola, Anna Maria Mazzucchetti, Mariangela Palladino, Giuliano Bertazzoni, Salvatore Minisola, Luigi Petramala, Luca Marino. Andrea Marletta, Marco De Cataldis, Daniele Corbi, Rosachiara Ansalone, Adriana D’Ercole, Serena Fontana, Paolo Rapisarda, Pietro Piccari, Giulia Marcelli, Michela Cascio, Valentina Di Manno, Margherita Ruggero, Giulia Cardillo Piccolino, Pierfrancesco Sinacori, Stefano Rossi, Domenico Di Vanna, Mauro Barbera, Maria Civita Cedrone, Valentina Di Biagio, Elisabetta Galati, Giulia Iacopelli, Annalisa Leonardi, Danilo Menichelli, Giovanni Franchino, Anna Criniti, Carla Labruno, Maria Santulli, Antonio Angeloni, Emiliano Lorusso, Simona Giglio.

Funding Open access funding provided by Università degli Studi diRoma La Sapienza within the CRUI-CARE Agreement.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Human and animal rights statement Not applicable.

Informed consent Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reference

1. Salamanna F, Maglio M, Landini MP, Fini M (2020) Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2. Front Med (Lausanne) 7:594495. https://doi.org/10.3389/fmed.2020.594495

2. Vora SM, Lieberman J, Wu H (2021) Inflammomass activation at the crux of severe COVID-19. Nat Rev Immunol 21(11):694–703. https://doi.org/10.1038/s41577-021-00588-x

3. Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L (2020) Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thromb Haemost 120(6):949–956. https://doi.org/10.1055/s-0040-1710317

4. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulos MA (2020) Organ-specific manifestations of COVID-19 infection. Clin Exp Med 20(4):493–506. https://doi.org/10.1007/s10238-020-00648-x

5. Wijayaratheraka K, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, Kim D (2021) COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol 33(7):990–995. https://doi.org/10.1097/MEG.0000000000001817

6. Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q (2021) Clinical determinants of the severity of COVID-19: a systematic review and meta-analysis. PLoS One 16(5):e0250602. https://doi.org/10.1371/journal.pone.0250602

7. Kovalic AJ, Huang G, Thuluvath PJ, Satapathy SK (2021) Elevated liver biochemistries in hospitalized Chinese patients with severe COVID-19: systematic review and meta-analysis. Hepatology 73(4):1521–1530. https://doi.org/10.1002/hep.31472

8. Oliva A, Borrazzo C, Mascellino MT, Curtolo A, Al Ismail D, Cancelli F, Galardo G, Bucci T, Ceccearelli G, d’Ettorre G, Pugliese F, Mastroianni CM, Venditti M (2021) CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia. Infez Med 29(3):408–415. https://doi.org/10.53855/lmim-2903-12

9. Sharma A, Jaiswal P, Kerakhan Y, Saravanan L, Murzata Z, Zergamh A, Honganur NS, Akbar A, Deol A, Francis B, Patel S, Mehta D, Jaiswal R, Singh J, Patel U, Malik P (2021) Liver disease and outcomes among COVID-19 hospitalized patients—a systematic review and meta-analysis. Ann Hepatol 21:100273. https://doi.org/10.1016/j.ahep.2020.10.001

10. Middleton P, Hsu C, Lythgoe MP (2021) Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol. https://doi.org/10.1136/bmjgast-2021-000739

11. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP (2010) Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59(9):1265–1269. https://doi.org/10.1038/gut.2010.216077

12. Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M (2020) Non-alcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol 18(10):2324-2331 e2324. https://doi.org/10.1016/j.cgh.2019.12.026

13. Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F (2018) Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol 264:58–63. https://doi.org/10.1016/j.ijcard.2018.01.097

14. Sterling RK, Shin D, Shin Y, French E, Stevens MP, Bajaj JS, DeWitt M, Sanyal AJ (2021) Fibrosis-4 predicts the need for mechanical ventilation in a national multiethnic cohort of corona virus disease 2019. Hepatol Commun 5(9):1605–1615. https://doi.org/10.1002/hep4.1737

15. Younossi ZM, Stepanova M, Lam B, Cable R, Felix S, Jeffers T, Younossi E, Pham H, Srishord M, Austin P, Estep M, Terra K, Escheik C, de Avila L, Golabi P, Kolacevski A, Racila A, Henry L, Gerber L (2021) Independent predictors of mortality among
patients with NAFLD hospitalized with COVID-19 infection. Hepatol Commun. https://doi.org/10.1002/hep4.1802

16. Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thrusr MR, Nayagam S, Manousou P (2020) In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One 15(10):e0240400. https://doi.org/10.1371/journal.pone.0240400

17. Sutandyo N, Kurniawati SA, Jayusman AM, Syafiyah AH, Pranata R, Hanafi AR (2021) Repurposing FIB-4 index as a predictor of mortality in patients with hematological malignancies and COVID-19. PLoS One 16(9):e0257775. https://doi.org/10.1371/journal.pone.0257775

18. Li Y, Regan J, Fajnzylber J, Coxen K, Corry H, Wong C, Rosenthal A, Atyeo C, Fischinger S, Gillespie E, Chishit R, Baden L, Yu XG, Alter G, Kim A, Li JZ (2021) Liver fibrosis index FIB-4 is associated with mortality in COVID-19. Hepatol Commun 5(3):434–445. https://doi.org/10.1002/hep4.1650

19. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845

20. Gandini O, Criniti A, Ballesio L, Giglio S, Galardo G, Gianni W, Santoro L, Angeloni A, Lubrano C (2020) Serum Ferritin is an independent risk factor for acute respiratory distress syndrome in COVID-19. J Infect 81(6):979–997. https://doi.org/10.1016/j.jinf.2020.09.006

21. Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, Pignatelli P, Pastori D (2020) Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest 50(10):e13378. https://doi.org/10.1111/eci.13378

22. Russo A, Gentilini Cacciola E, Borrazzo C, Filippi V, Buccu T, Vullo F, Celani L, Binetti E, Battistini L, Ceccarelli G, Alessandrini M, Galardo G, Mastroianni CM, d’Ettorre G (2021) Clinical characteristics and outcome of patients with suspected COVID-19 in emergency department (RESILIENCY Study II). Diagnostics (Basel). https://doi.org/10.3390/diagnostics11081368

23. Ramos-Lopez O, San-Cristobal R, Martinez-Urbistondo D, Mico V, Colmenarejo G, Villares-Fernandez P, Daimiel L, Martinez JA (2021) Proinflammatory and hepatic features related to morbidity and fatal outcomes in COVID-19 patients. J Clin Med. https://doi.org/10.3390/jcm1014112

24. Crisan D, Avram L, Grapa C, Dragan A, Radulescu D, Crisan S, Grosu A, Militaru V, Buzdugan E, Stoicescu L, Radulescu L, Cioviccescu F, Jivanescu DB, Moscan O, Micu B, Donca V, Marinescu L, Macarie A, Rosu M, Nemes A, Craciun R (2021) Liver injury and elevated FIB-4 define a high-risk group in patients with COVID-19. J Clin Med. https://doi.org/10.3390/jcm11010153

25. Covino M, De Matteis G, Polla DAD, Santoro M, Burzo ML, Torelli E, Simeoni B, Russo A, Sandroni C, Gasbarrini A, Franceschi F (2021) Predictors of in-hospital mortality and death risk stratification among COVID-19 patients aged >/= 80 YEARS OLD. Arch Gerontol Geriatr 95:104383. https://doi.org/10.1016/j.archger.2021.104383

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.